Harihar Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.80 M
as on 16-11-2024
- Paid Up Capital ₹ 1.80 M
as on 16-11-2024
- Company Age 36 Year, 12 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.27 M
as on 16-11-2024
- Satisfied Charges ₹ 9.50 M
as on 16-11-2024
- Revenue -35.83%
(FY 2023)
- Profit -39.65%
(FY 2023)
- Ebitda -17.37%
(FY 2023)
- Net Worth 11.57%
(FY 2023)
- Total Assets 16.49%
(FY 2023)
About Harihar Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.80 M and a paid-up capital of Rs 1.80 M.
The company currently has active open charges totaling ₹9.27 M. The company has closed loans amounting to ₹9.50 M, as per Ministry of Corporate Affairs (MCA) records.
Kanhaiya Agrawal, Binaya Goyal, and Bibek Goyal serve as directors at the Company.
- CIN/LLPIN
U24231OR1989PTC002155
- Company No.
002155
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jan 1989
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Balangir, Odisha, India
- Telephone
- Email Address
- Website
-
- Social Media
Who are the key members and board of directors at Harihar Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kanhaiya Agrawal  | Managing Director | 11-Jan-2001 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Binaya Goyal | Director | 18-Aug-2004 | Current |
| Bibek Goyal | Director | 18-Aug-2004 | Current |
Financial Performance of Harihar Pharmaceuticals.
Harihar Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 35.83% decrease. The company also saw a substantial fall in profitability, with a 39.65% decrease in profit. The company's net worth Soared by an impressive increase of 11.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harihar Pharmaceuticals?
In 2023, Harihar Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 15 Nov 2021 | ₹9.27 M | Open |
Idbi Bank Limited Creation Date: 12 Jan 2018 | ₹4.00 M | Satisfied |
Utkal Gamya Bank Creation Date: 16 Dec 2005 | ₹5.50 M | Satisfied |
How Many Employees Work at Harihar Pharmaceuticals?
Harihar Pharmaceuticals has a workforce of 10 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harihar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harihar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
